Holen Sie sich die Stockscreener-App
140.55
0.48%
-0.68
Vorhandelsmarkt:
141.00
0.45
+0.32%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$141.23
Offen:
$143.13
24-Stunden-Volumen:
1.07M
Relative Volume:
0.75
Marktkapitalisierung:
$20.48B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.62B
KGV:
12.70
EPS:
11.07
Netto-Cashflow:
$1.77B
1W Leistung:
-5.56%
1M Leistung:
-6.70%
6M Leistung:
-38.44%
1J Leistung:
-42.70%
1-Tages-Spanne:
$140.06
$143.50
1-Wochen-Bereich:
$140.05
$150.48
52-Wochen-Spanne:
$140.05
$252.17
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
140.55 | 20.48B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Sage sues partner Biogen after unsolicited takeover offer - PharmaLive
Alzheimer's Drugs Market Growth: AbbVie, Amgen, and Biogen Pioneering New Therapeutic Solutions - openPR
Guardian Investment Management Sells 2,865 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sax Wealth Advisors LLC Invests $337,000 in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Avanza Fonder AB Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Announces New Chief Accounting Officer Appointment - MSN
Sage sues Biogen after unsolicited takeover bid - pharmaphorum
BRIEF—Biogen sued by Sage after buyout offer - The Pharma Letter
Wedge Capital Management L L P NC Acquires 26,530 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says - MSN
Biogen (NASDAQ:BIIB) Sets New 52-Week LowHere's What Happened - MarketBeat
Biogen Beats Humana's RICO Suit Over MS Drug Scheme on Appeal - Bloomberg Law
Sage sues Biogen in wake of $469M buyout offer: report (BIIB:NASDAQ) - Seeking Alpha
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review - MSN
Alzheimer’s drugs eyed as next big obesity-like opportunity - The Keene Sentinel
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt - Benzinga
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1) - Bloomberg Law
Biogen's Quarterly Earnings Preview: What You Need to Know - Nasdaq
Biogen's Quarterly Earnings Preview: What You Need To Know - Barchart
Biogen Inc. Announces Executive Changes Effective March 1, 2025 -January 15, 2025 at 08:00 am EST - Marketscreener.com
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates - Yahoo Finance
The Escalator: Lykos Therapeutics, Biogen, CMI Media Group and more - MM+M Online
Czech National Bank Acquires 1,923 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedmont Private Capital Boosts Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen stock at lowest level since February 2013 following J.P. Morgan presentation - MSN
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Short Interest in Biogen Inc. (NASDAQ:BIIB) Increases By 42.6% - MarketBeat
Biogen stock stays strong with Outperform rating as Oppenheimer highlights disciplined growth strategy - Investing.com India
Biogen appoints new Chief Accounting Officer - Investing.com
OIG raises concerns about accelerated approval deviations - BioWorld Online
At JPM, Biogen CEO tries to take down the deal temperature - BioPharma Dive
Biogen Inc. (BIIB) Appoints New Chief Accounting Officer - GuruFocus.com
Biogen Says It's 'Doubling Down' on Alzheimer's Disease at JPM - Precision Medicine Online
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders - Seeking Alpha
Under Pressure to Deal, Biogen Executives Deflect Urgency at JPM25 - BioSpace
JPM25 day two: Roche, Amgen, Merck, Lilly, and Biogen - PharmaLive
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More - BioSpace
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs - BioSpace
Biogen CEO Discusses Strategy to Rely on New Product Launches for GrowthNews and Statistics - IndexBox, Inc.
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen - BioSpace
Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug - PMLiVE
Biogen lays out three FDA decisions that could ramp up Alzheimer's drug launch - The Business Journals
Biogen CEO targets faster dementia treatment launch with new subcutaneous Leqembi optionCHOSUNBIZ - 조선비즈
Alport Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - Barchart
Biogen Looks Ahead With Confidence As New Products Take Charge - Finimize
JPM25: Biogen 'doubling down' on Alzheimer's in long bet - FirstWord Pharma
Biogen CEO sees no burning need for more acquisitions - Reuters
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Sarepta, Biogen drugs with accelerated approval under fire in FDA report - Seeking Alpha
JPM25, Day 2: Biogen ready to stand its ground in Alzheimer's showdown, CEO says - FiercePharma
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):